Cholecalciferol Supplementation and Transplant Outcomes Across Immunosuppressive Regimens in Renal Transplant Recipients Using the United States Food and Drug Administration Adverse Event Reporting System
Cureus · 12.03.2026
DOI: 10.7759/cureus.105141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 12.03.2026. Verfasst von Toru Ogura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Support Center, Mie University Hospital, Tsu, JPN. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Research Support Center, Mie University Hospital, Tsu, JPN.
- Department of Pharmaceutical Sciences for Health Crisis Management, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, JPN.
- Department of Clinical Nutrition, Mie University Hospital, Tsu, JPN.
- Organ Transplantation Center, Mie University Hospital, Tsu, JPN.
Zitieren
APA
Ogura, T., Shiraishi, C., Asakura, A., & Urawa, A. (2026). Cholecalciferol Supplementation and Transplant Outcomes Across Immunosuppressive Regimens in Renal Transplant Recipients Using the United States Food and Drug Administration Adverse Event Reporting System. Cureus. https://doi.org/10.7759/cureus.105141
Vancouver
Ogura T, Shiraishi C, Asakura A, Urawa A. Cholecalciferol Supplementation and Transplant Outcomes Across Immunosuppressive Regimens in Renal Transplant Recipients Using the United States Food and Drug Administration Adverse Event Reporting System. Cureus. 2026. doi:10.7759/cureus.105141
BibTeX
@article{Ogura2026,
author = {Ogura, Toru and Shiraishi, Chihiro and Asakura, Akie and Urawa, Aiko},
title = {Cholecalciferol Supplementation and Transplant Outcomes Across Immunosuppressive Regimens in Renal Transplant Recipients Using the United States Food and Drug Administration Adverse Event Reporting System},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.105141}
}
EUVIMED